Kexing Biotech’s wholly-owned subsidiary is approved to conduct clinical trials of GB18 injection
May 28, 2025
Source: drugdu
84
On May 26, Kexing Pharmaceuticals issued an announcement that recently, the company's wholly-owned subsidiary Shenzhen Kexing Pharmaceutical Co., Ltd. received the "Drug Clinical Trial Approval Notice" issued by the National Medical Products Administration, approving it to conduct clinical trials of "GB18 Injection".
The injection is an innovative drug targeting GDF15, designed to treat tumor cachexia. Preclinical data show that GB18 injection has obvious differentiated advantages, can effectively reverse weight loss caused by tumor cachexia, and improve muscle and fat quality.
In the first quarter of 2025, Kexing Biotech achieved revenue of 354 million yuan and net profit attributable to shareholders of the parent company of 25.58 million yuan.
https://finance.eastmoney.com/a/202505263414629127.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- Innovent Biologics’ Suvicitamab is approved for marketing, solving the dilemma in the treatment of platinum-resistant ovarian cancer July 7, 2025
- Everest Medicines’ Next-Generation BTK Inhibitor EVER001 Announces Latest Clinical Results, Continues to Demonstrate Efficacy and Safety July 7, 2025
- Jinsai Pharmaceutical’s Fuxin Qibaimab was approved, reducing the risk of gout recurrence by 87% in half a year July 7, 2025
- LH-1801 project enters Phase III clinical trial July 7, 2025
- The new generation of DNA biosynthesis technology is moving towards industrialization July 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
